Amicus Therapeutics Announces Executive Team Updates
Daphne Quimi Promoted to Chief Financial Officer
David Clark Joins as Chief People Officer
Ellen Rosenberg Promoted to Chief Legal Officer
Mr. Crowley stated, “Amicus has never been in a stronger financial position, thanks to the leadership of Chip, Daphne and our extraordinary global finance team. We have become a truly worldwide company now with operations in more than 27 countries and world class financial reporting, controls and accounting systems. Our balance sheet has never been more sound. Daphne has been instrumental in building this global finance organization during her tenure at Amicus. Her extensive executive experience will help lead us through the next chapter of our growth and toward our vision to become one of the world’s leading biotechnology companies focused on rare diseases. I am confident that the hand-off from Chip to Daphne will be smooth. I will remain forever grateful to Chip for his extraordinary leadership and passion for patients and wish him well in his future endeavors. He leaves Amicus in a very strong position.”
Ms. Quimi stated, “I am proud to have been a part of the Finance team as we have transitioned to a public company and now into a global commercial company. I look forward to taking on the responsibilities of Chief Financial Officer as we continue to execute the Galafold launch, move our Pompe program into Phase 3, and advance our gene therapy pipeline.”
Ms. Quimi joined Amicus in
Mr. Baird stated, “We have accomplished a great deal at Amicus over the last seven years. Working with John and the rest of the leadership team, we have transformed Amicus from a US-based R&D company to a global commercial company with one of the strongest pipelines in rare disease. With a very strong balance sheet, a growing commercial business in Galafold, and a capable finance leader like Daphne, Amicus is well-positioned to deliver on the next phase of its patient-focused mission.”
Additional Organizational Updates and Promotions
- David Clark Appointed Chief People Officer:
David Clark has joined Amicus as the first Chief People Officer, reporting to Mr. Crowley. Mr. Clark has been a leader in human resources and talent development for more than two decades. Before joining Amicus, Mr. Clark spent two years as Vice President of Global Human Resources atAlibaba Group inHangzhou, China . Previously, he spent eight years atAmerican Express , where he was Senior Vice President of HR and Chief Learning Officer. Before that, Mr. Clark was a Commissioned Officer on theWhite House senior staff, responsible for the recruitment and development of the 4,000 most senior leaders in the U.S. government.
- Ellen Rosenberg Promoted to Chief Legal Officer:
Ellen Rosenberg joined Amicus in February of 2016 as General Counsel and Corporate Secretary, reporting to Mr. Crowley. She has overseen the build out of the global legal team to support commercialization, business development and real estate transactions and provides valuable strategic counsel to senior management and the Amicus Board of Directors.
Andrew E. Mulberg , MD, FAAP, CPI Promoted from VP to SVP, Global Regulatory Affairs: Dr. Mulberg, the former Deputy Director of theFDA Division of Gastroenterology and Inborn Errors Products , reports toJay Barth , MD, Chief Medical Officer. Since joining Amicus inJuly 2016 , he has been responsible for directing global regulatory activities for all Amicus programs to bring multiple therapies to patients with rare and devastating diseases.
Anthony Sileno , MS Promoted from VP to SVP, Clinical Operations and Translational Sciences: Mr. Sileno has more than 30 years of experience in drug development. He joined Amicus inFebruary 2016 fromNPS Pharmaceutical Company (acquired by Shire) and reports to Dr. Barth. He provides the leadership and strategic direction required for the successful execution of all operational aspects of clinical trials, translational sciences and management of toxicology studies within Amicus.
Mr. Crowley continued, “I am pleased to welcome David to Amicus as our first-ever Chief People Officer. He will be a tremendous asset to our organization as we continue to grow our global team while affirming our patient-dedicated culture. I would also like to congratulate Ellen, Andrew and Anthony on their promotions. All of them are exceptional leaders and provide expertise that add significant value within their respective functions and throughout the Company.”
About
Forward-Looking Statements
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. The inclusion of forward-looking statements should not be regarded as a representation by us that any of our plans will be achieved. Any or all of the forward-looking statements in this press release may turn out to be wrong and can be affected by inaccurate assumptions we might make or by known or unknown risks and uncertainties. In addition, all forward-looking statements are subject to other risks detailed in our Annual Report on Form 10-K for the year ended
CONTACTS:
Investors/Media:
Vice President, Investor Relations & Corporate Communications
spellegrino@amicusrx.com
(609) 662-5044
Media:
jpaganelli@purecommunications.com
(347) 658-8290
FOLD–G
Source: Amicus Therapeutics, Inc.